Join BIOCYTOGEN at Stanford Drug Discovery Symposium 2025
January 16, 2025
We’re excited to share that Biocytogen will be exhibiting at the Stanford Drug Discovery Symposium 2025! Mark your calendars for April 28–29 in Stanford, CA, where leading biotechnology companies and innovators gather to highlight transformative advancements. This renowned event offers exceptional networking opportunities, bringing together top scientists, investors, and biopharmaceutical leaders to foster collaboration and […]
Join BIOCYTOGEN at Bio EU Spring 2025
January 14, 2025
We’re pleased to share that we will be exhibiting at BIO-Europe Spring 2025! Scheduled from March 17th to 19th in Milan, Italy, this prestigious event offers a key stage for biotechnology companies to present their cutting-edge advancements. Providing unmatched opportunities for networking, BIO-Europe Spring brings together innovators, investors, and biopharmaceutical leaders to foster collaboration and […]
Join BIOCYTOGEN at World ADC London 2025
January 14, 2025
We’re excited to announce our participation as an exhibitor at World ADC London Showcase 2025! From March 3rd to 6th in London, UK, this leading event serves as a critical platform for biotechnology companies to highlight groundbreaking advancements. With unparalleled opportunities for direct engagement, World ADC fosters meaningful connections between innovators, investors, and biopharmaceutical leaders, […]
Join BIOCYTOGEN at AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS 2025
January 9, 2025
We’re thrilled to announce that we’ll be exhibiting at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025! Join us from April 27th – 30th in Chicago, Illinois, at this prestigious event where biotechnology companies showcase groundbreaking advancements. With unparalleled networking opportunities, this conference unites innovators, investors, and biopharmaceutical leaders to drive collaboration […]
Biocytogen Announces Licensing of Fully Human Antibodies with SOTIO to Develop Novel ADC SOT109 for Colorectal Cancer Treatment
January 9, 2025
Beijing, China, and Prague, Czech Republic, January 9, 2025 – Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing novel antibody therapeutics, announced the licensing of its fully human antibodies to SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group. The licensing agreement will advance the development of an innovative antibody-drug […]
Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors
January 7, 2025
Collaboration initiates development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs) Biocytogen’s RenLite® meets Acepodia’s AD2C for precision oncology solutions BEIJING, ALAMEDA, Calif. and TAIPEI, January 7 – Biocytogen (HKEX: 02315) and Acepodia (6976:TT), today announced a groundbreaking strategic partnership to jointly assess a dual-payload bispecific antibody-drug conjugate (BsAD2C) program. This collaboration combines Biocytogen’s RenLite® platform with Acepodia’s […]
Behind the Scenes: Meet Ravneet: Innovating in Biotech and Beyond
December 17, 2024
At Biocytogen, innovation thrives with dynamic team members like Ravneet. A globe-trotter and experimental baker, she’s always ready for adventure—whether hiking national parks or creating fusion dishes. In the Business Development team, her knack for navigating diverse client needs and time zones drives her success. With positivity and precision, she tackles complex preclinical research challenges […]
Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development
December 16, 2024
Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development Adcendo exercises its option to utilize Biocytogen’s fully human antibodies to further expand its ADC pipeline for cancers with high unmet medical need This collaboration further validates Biocytogen’s proprietary RenMice® antibody discovery platform, demonstrating its potential to advance innovative therapies for patients BEIJING, China, […]
Join BIOCYTOGEN at CBA-GP Biomedical Science Symposium 2025
December 12, 2024
We’re proud to share that we’ll be exhibiting at the CBA-GP Biomedical Science Symposium 2025! Scheduled for February 8th in Philadelphia, this prestigious event offers an invaluable stage for biotech companies to highlight their cutting-edge innovations. Providing unique opportunities for direct connections with investors and industry leaders, the symposium encourages collaboration and paves the way […]
Join BIOCYTOGEN at BIO Partnering @JPM Week
December 11, 2024
We’re excited to share that we’ll be exhibiting at BIO Partnering @JPM Week 2025! Happening January 13th to 16th in San Francisco, California, this renowned event provides an essential stage for biotechnology companies to showcase their innovative breakthroughs. It’s a unique opportunity to connect directly with investors and biopharmaceutical leaders, sparking collaboration and advancing progress […]
